Geron Corp. (GERN)
Last updated: 2026-10-20 15:47:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Geron Corp. (GERN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.23, with a market capitalization of $751.69M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.04 to $2.01. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$751.69M | |
$1.20 | |
$16.80 | |
$0.75 | |
$1.20 | |
1.32M | |
9.91M | |
-- | |
$2.01 | |
$1.04 | |
-- | |
-- |
Geron Corp. (GERN) Stock Price Today
Geron Corp. (GERN) is currently trading at $1.23 as of 2026-10-20 15:45:00, up 2.08% ($0.03) from the previous close of $1.20
During today's regular trading session, GERN has traded between $0.75 and $16.80, with a trading volume of 1.32M shares. The current price is near the lower end of today's range.
Geron Corp. (GERN) 7-Day Stock Price Change
Over the past seven days, Geron Corp. (GERN) moved from $1.23 to $1.23, representing no net price change.
The stock traded between $1.17 and $1.26 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 5.31 million shares, down versus the previous seven-day period, indicating lower trading activity.
GERN 52-Week Price Position
Position in Range: 19.1%
GERN is currently trading at $1.23, placing it 19.1% of the way from its 52-week low of $1.04 to its 52-week high of $2.01. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Geron Corp. (GERN)?
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Geron Corp. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 258 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Geron Corp. (GERN) Stock on MEXC
Eligible investors can buy real shares of Geron Corp. (GERN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Geron Corp. (GERN) stock price today?
2.Is GERN stock going up or down today?
3.What is GERN pre-market price?
4.What is GERN after-hours price?
5.Is GERN stock trading now?
6.Where does GERN sit relative to its 52-week high and low?
7.What sector is Geron Corp. in?
8.What is Geron Corp.'s market capitalization and where is it listed?
9.How is GERN valued in terms of P/E ratio and EPS?
10.Does Geron Corp. pay a dividend?
Explore More US Stocks
Search Stocks
GERN Stock Calculator
Estimate the value between GERN shares and USD.
GERN Shares to USD
1.00 GERN shares = 1.225 USD
Calculations are estimates based on the latest available price and are for reference only.


